This year, millions of basketball fans will be watching college basketball teams battle it out for the NCAA Men’s Basketball Championship, but many of these same schools are also high scorers when it comes to research programs. Our IP & Science business just launched Metrics Mania, to measure the research impact of American universities participating in the NCAA Tournament.
Metrics Mania winners will be determined weekly from reportspulled from Thomson Reuters InCitesTM, a robust, web-based evaluation tool that analyzes a university’s research productivity and performance based on citation data derived from Thomson Reuters Web of KnowledgeSM. The brackets in Metrics Mania will align competing institutions in six rounds to see how research programs compare. Each week fans can view how their favorite schools/teams perform. (more…)
Drug approvals by the FDA reached a 16-year high in 2012: with 39 new drug approvals, this was the second highest figure in at least two decades. It’s still too early to tell whether this trend will continue into 2013, but we have some early insights into the latest pharmaceutical approval activities in the most recent The Ones to Watch report. The Ones to Watch is the best source on the most promising drugs changing clinical phase, receiving approval and launched from October to December 2012.
To capture a better understanding of their progress, we reviewed data on R&D spending, human capital, research publications, and patent filings—key indicators of the sustained, diversified research innovation base enjoyed by many of the G7 knowledge economies. The data not only confirm and quantify the rising status of countries beyond the G7 axis as a group, but also spotlight the individual complexities that offer a richer tapestry behind the “emerging” label.
Lung cancer has the highest mortality rate of all cancers and is the second most commonly diagnosed cancer in both men and women. Cancers of the lung are aggressive and treatment remains a significant challenge, however, the discovery and development of molecular targeted agents have had a major impact on the treatment of non-small-cell lung cancer (NSCLC) in the last decade and there is now a range of personalized approaches to treat the disease.
After being a proud sponsor of the 2012 Grace Hopper Women in Computing Conference, we wanted to take the opportunity to highlight some of our own women in computing. In this installment, meet Sejal Amin, VP Life Sciences Technology, IP & Science.
What do you do at Thomson Reuters?
I am responsible for the management of the Life Sciences Technology team within IP & Science Technology. The team is responsible for the development life cycle of all Life Sciences related products. Our single biggest initiative is the migration of all Life Sciences content to a single platform reducing cost, enabling retention and creating new growth opportunities. My key role is managing and evolving a geographically dispersed development team to become a truly integrated technology organization.
14 Dec 2012Thomson Reuters
Where do your technology skills/background/experiences come into play in that work?
Managing technologies and technology professionals requires a balance of so many different skills; it is about being aware of your own strengths to leverage them in the many situations you are faced with every day, as well as being cognizant of your development areas so that you can spend time on growing yourself.
What excites you most about working in technology?
It requires incredible amounts of energy, passion, commitment and allows you to wear multiple hats in a single day. Because it is a fast moving industry, it is a continuous educational experience challenging me to think about new and better ways to get things done. I have been able to settle into an environment that allows me to leverage my strengths as well as evolve as a professional.
What attributes do you think are critical to a successful technology career? (more…)
We are pleased to announce the 2012 Top 100 Global Innovators list, honoring 100 corporations and institutions around the world that are at the heart of innovation as measured by a series of proprietary patent-related metrics.
Financial analysis of the acknowledged companies gives credence to their significance in that these organizations outperformed the S&P 500 by three percent in their market cap weighted revenue (15 percent versus 12 percent). This year’s winners also added 124,214 new jobs over their prior year employment figures. (more…)
Our Intellectual Property & Science business has launched the Data Citation Index, a research resource within the Web of Knowledge to facilitate the discovery, use and attribution of data sets and data studies that also link to peer-reviewed literature.
This new research resource from Thomson Reuters creates a single source of discovery for scientific, social sciences and arts and humanities information. It provides a single access point to discover foundational research within data repositories around the world in the broader context of peer-reviewed literature in journals, books, and conference proceedings already indexed in the Web of Knowledge. (more…)
Thomson CompuMark, the global leader in trademark searching and brand protection solutions, has completed the addition of 136 new databases in its SAEGIS on SERION online trademark screening solution. With this new content, Thomson CompuMark has become the undisputed world’s largest provider of comprehensive trademark screening data, covering 186 countries and registers.
The implementation of the additional databases, referred to as “One World. One Source.” contains new trademark data from emergent regions in Central and South America, Asia and the Middle East. The process of building the databases involved gathering public information via networks, publications and third parties as well as leveraging exclusive internal sources. The result is a user-friendly, one-stop solution containing a thoroughly vetted, reliable and comprehensive collection of searchable trademarks from any registrar in the world. Most databases are available exclusively through SAEGIS.